Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway
暂无分享,去创建一个
[1] Jianlin Du,et al. Transcriptomic profile analysis of the left atrium in spontaneously hypertensive rats in the early stage , 2022, Frontiers in Pharmacology.
[2] M. Dörr,et al. Myeloid differentiation factor‐2 activates monocytes in patients with dilated cardiomyopathy , 2022, Immunology.
[3] Jianlin Du,et al. The Relationship between Abnormal Circadian Blood Pressure Rhythm and Risk of Readmission in Patients with Heart Failure with Preserved Ejection Fraction , 2021 .
[4] Zhan Ye,et al. Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols , 2020, RNA.
[5] Jianlin Du. Risk of Target Organ Damage in Patients with Masked Hypertension versus Sustained Hypertension: A Meta-analysis , 2020 .
[6] G. Filippatos,et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.
[7] F. Cosentino,et al. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.
[8] E. Sanidas,et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension. , 2019, American journal of hypertension.
[9] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[10] S. Terra,et al. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials , 2019, Cardiovascular Diabetology.
[11] Fen Li,et al. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload , 2019, American journal of hypertension.
[12] L. V. Van Laake,et al. Circadian rhythms and the molecular clock in cardiovascular biology and disease , 2019, Nature Reviews Cardiology.
[13] K. Connelly,et al. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction , 2019, JACC. Basic to translational science.
[14] Halina Dobrzynski,et al. Circadian rhythm of cardiac electrophysiology, arrhythmogenesis, and the underlying mechanisms , 2019, Heart rhythm.
[15] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[16] K. Kario,et al. Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension , 2018, Circulation.
[17] K. Kario,et al. 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study. , 2018, Circulation.
[18] N. Fukuda,et al. The adrenal gland circadian clock exhibits a distinct phase advance in spontaneously hypertensive rats , 2018, Hypertension Research.
[19] A. Nakashima,et al. Dec1 and CLOCK Regulate Na+/K+-ATPase &bgr;1 Subunit Expression and Blood Pressure , 2018, Hypertension.
[20] A. Nishiyama,et al. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity , 2018, Front. Endocrinol..
[21] S. Chon,et al. Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial , 2018, Diabetes, obesity & metabolism.
[22] A. Vaag,et al. MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? , 2018, European journal of endocrinology.
[23] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[24] I. Tikkanen,et al. Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension , 2017, Diabetes, obesity & metabolism.
[25] S. Verma,et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure , 2017, JACC. Basic to translational science.
[26] A. Kengne,et al. Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients , 2017, Journal of the American Heart Association.
[27] I. J. Lynch,et al. Desoxycorticosterone pivalate‐salt treatment leads to non‐dipping hypertension in Per1 knockout mice , 2017, Acta physiologica.
[28] Dave L Dixon,et al. Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.
[29] A. Nishiyama,et al. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats , 2017, Clinical and experimental pharmacology & physiology.
[30] F. Alibhai,et al. Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease. , 2017, Journal of molecular and cellular cardiology.
[31] Joseph S. Takahashi,et al. Transcriptional architecture of the mammalian circadian clock , 2016, Nature Reviews Genetics.
[32] M. Al-Omran,et al. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? , 2016, Diabetes Care.
[33] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[34] M. Elisaf,et al. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors , 2016, Expert opinion on pharmacotherapy.
[35] Yoshiya Tanaka,et al. A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin. , 2016, Journal of UOEH.
[36] A. Nishiyama,et al. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats , 2016, Hypertension Research.
[37] Michelle L. Gumz,et al. Transcriptional regulation of NHE3 and SGLT1 by the circadian clock protein Per1 in proximal tubule cells. , 2015, American journal of physiology. Renal physiology.
[38] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[39] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[40] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[41] Jacob Richards,et al. Clock genes in hypertension: novel insights from rodent models , 2014, Blood pressure monitoring.
[42] I. Tikkanen,et al. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.
[43] Hong-Xia Wang,et al. NADPH oxidases mediate a cellular "memory" of angiotensin II stress in hypertensive cardiac hypertrophy. , 2013, Free radical biology & medicine.
[44] Chao-shu Tang,et al. Role for granulocyte colony stimulating factor in angiotensin II-induced neutrophil recruitment and cardiac fibrosis in mice. , 2013, American journal of hypertension.
[45] D. de Zeeuw,et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.
[46] Hui-Hua Li,et al. Carboxyl terminus of heat shock protein 70-interacting protein inhibits angiotensin II-induced cardiac remodeling. , 2012, American journal of hypertension.
[47] D. Duncker,et al. Apelin Enhances Cardiac Neovascularization After Myocardial Infarction by Recruiting Aplnr+ Circulating Cells , 2012, Circulation research.
[48] Günter P. Wagner,et al. Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples , 2012, Theory in Biosciences.
[49] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[50] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[51] Ruiqiang Li,et al. SOAP: short oligonucleotide alignment program , 2008, Bioinform..
[52] H. Abdi. The Bonferonni and Šidák Corrections for Multiple Comparisons , 2006 .
[53] E. Nishida,et al. Involvement of the MAP kinase cascade in resetting of the mammalian circadian clock. , 2000, Genes & development.
[54] S. Izumo,et al. Calcineurin—the missing link in cardiac hypertrophy , 1998, Nature Medicine.
[55] B. A. Harder,et al. Signaling pathways in cardiac myocyte hypertrophy. , 1997, Journal of molecular and cellular cardiology.
[56] E. Nishida,et al. Involvement of the MAP kinase cascade in Xenopus mesoderm induction. , 1995, The EMBO journal.
[57] P. Poole‐Wilson,et al. Cellular mechanisms of cardiac hypertrophy. , 1995, British heart journal.